文献速递肿瘤 PET/CT核素与放射性配体治疗放射性药物与辐射防护

FDG-PET/CT评估肿瘤、富淋巴器官与免疫相关不良事件预测免疫治疗反应

Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT.
PubMed 文献 · Clin Nucl Med · 2019-01-01

该回顾性研究纳入40例接受免疫检查点抑制剂治疗的患者(恶性黑色素瘤21例、恶性淋巴瘤11例、肾细胞癌8例),于治疗前后行FDG-PET/CT,评估肿瘤、脾、骨髓、甲状腺和垂体的SUVmax及免疫相关不良事件(IRAE)与疗效的关系。结果显示临床获益者肿瘤参数显著下降(P<0.001),甲状腺SUVmax升高>1.5者均达完全缓解,PET可检测的IRAE有助于预测良好结局。

要点

  • 早期FDG-PET/CT显示肿瘤参数下降与免疫治疗临床获益相关(P<0.001)。
  • 首次再分期甲状腺SUVmax升高>1.5的5例患者1年内均达完全缓解。
  • PET可检测的IRAE(尤其甲状腺炎)可能提示免疫治疗良好结局。

核心结论

  • 免疫治疗早期FDG-PET/CT肿瘤参数下降见于1年内临床获益患者。
  • PET可检测的IRAE有助于预测良好结局,甲状腺炎早发可能是早期反应指标。

研究设计与样本

  • 病种包括恶性黑色素瘤21例、恶性淋巴瘤11例、肾细胞癌8例。
  • 评估基线与首次再分期扫描中肿瘤、脾、骨髓、甲状腺和垂体的SUVmax,并与治疗第一年最佳总体反应相关分析。

主要发现

  • 临床获益患者基线与首次再分期之间肿瘤参数显著下降(P<0.001)。
  • 首次再分期甲状腺SUVmax升高>1.5的5例患者1年内均达完全缓解(CR)。
  • 1年内达CR的22例患者与良好长期结局显著相关(P=0.002)。
  • 9例有IRAE表现的患者最终评估达CR。
  • IRAE中甲状腺炎出现显著早于关节炎(P=0.040)。

关键数值与推荐

  • 甲状腺SUVmax较基线升高>1.5(n=5)者1年内均达CR。
  • 1年内CR(n=22)与良好长期结局相关(P=0.002)。
  • 甲状腺炎出现早于关节炎(P=0.040)。

临床怎么用

  • 免疫治疗前后可用FDG-PET/CT评估肿瘤SUVmax变化及富淋巴器官SUVmax变化。
  • 关注甲状腺SUVmax升高>1.5及甲状腺炎等IRAE,可能提示治疗反应。

局限性

  • 回顾性研究,样本量40例,病种异质。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate whether the evaluation of tumors, lymphoid cell-rich organs, and immune-related adverse events (IRAE) with F-FDG PET/CT can predict the efficacy and outcome of immunotherapy. METHODS: Forty patients who underwent F-FDG-PET/CT scans before and after therapy with immune checkpoint inhibitors from December 2013 to December 2016 were retrospectively enrolled (malignant melanoma, n = 21; malignant lymphoma, n = 11; renal cell carcinoma, n = 8). SUVmax of the baseline and first restaging scans were evaluated in tumors, spleen, bone marrow, thyroid and pituitary glands, and were correlated to best overall response in the first year after therapy; IRAE-affected areas were also evaluated. RESULTS: Interval change between the baseline and first restaging scans showed that patients with a clinical benefit had a significant decrease in tumor parameters (P < 0.001). All patients with an increase of SUVmax in the thyroid of more than 1.5 (n = 5) on the first restaging scan had a complete response (CR) in 1 year. Patients with CR within 1 year (n = 22) were significantly associated with a favorable long-term outcome (P = 0.002). Nine patients with IRAE findings had CR at final evaluation. Among IRAE, thyroiditis was seen significantly earlier than arthritis (P = 0.040). CONCLUSIONS: The decrease of tumor parameters at early time-point PET scans was seen in patients with immunotherapy who had clinical benefit within 1 year. PET-detectable IRAE was useful for prediction of a favorable outcome. Early development of thyroiditis may particularly represent an early response indicator to immunotherapy.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Nobashi T, Baratto L, Reddy SA, et al. Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT. Clin Nucl Med. 2019. PMID: 30688730. doi:10.1097/RLU.0000000000002453

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。